Stéphanie Gachet
Has grant
Chercheuse contractuelle
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Rôle des mutations de TP53 dans les mécanismes de résistance et de rechute des leucémies aiguës lymphoblastiques T (LAL-T) et ciblage thérapeutique
Open Date: 2022-04-01
Close Date: 2026-04-01
Grant: Close
« Étude du rôle des mutations de TP53 dans les mécanismes de résistance et de rechute des leucémies aiguës lymphoblastiques T (LAL-T) et ciblage thérapeutique
Open Date: 2019-12-01
Close Date: 2021-12-01
Articles (7)
Although most patients with T-cell acute lymphoblastic leukemia (T-ALL) achieve remission with chemotherapy, many relapse with a poor prognosis, treatment-resistant disease. The mechanisms driving chemoresistance remain largely elusive, in part due to the lack of faithful experimental models. Here, we generated isogenic patient-derived xenograft (PDX) pairs at diagnosis and relapse from T-ALL cases harboring TP53 alterations at relapse ( TP53 alt , TP53 mutation and/or deletion). These models faithfully captured the genomic and functional features of both the diagnosis and the relapse primary leukemias. Despite inter-T-ALL variability, comparative functional analyses revealed a unique, cell-intrinsic relapse phenotype that includes enhanced leukemia-initiating capacity and which can be experimentally conferred to diagnosis cells by TP53 silencing. Deregulated metabolic pathways and increased MYC signaling are prominent in the relapse phenotype. Ultra-sensitive backtracking of TP53 -mutant cells and single-cell expression profiling revealed cellular heterogeneity at diagnosis, with sequential progression from a minor subpopulation toward a biallelic TP53 alt relapse. Our findings support a model in which T-ALL relapse originates from a pre-existing transcriptional state with deregulated metabolism that is selected under therapeutic pressure, opening monitoring prospects for precision medicine.
Year:
2026
Acute megakaryoblastic leukemia (AMKL) is a rare and aggressive pediatric acute myeloid leukemia subtype, frequently driven by the ETO2::GLIS2 (EG) gene fusion in de novo AMKL patients. The EG fusion confers poor prognosis and high relapse risk. In a previous study, we demonstrated that human fetal hematopoietic cells are intrinsically permissive to EG-driven transformation and that microenvironmental cues critically enhance leukemogenesis in less permissive human cord blood (CB) cells. However, most pediatric AML models are established in adult recipient mice, potentially overlooking developmental niche-specific effects. Here, we investigated whether mouse neonates provide a more permissive environment for EG-driven leukemogenesis from human CB hematopoietic stem and progenitor cells (HSPCs). Comparison of xenotransplants of EG-transduced CB CD34 + cells into sublethally irradiated NSG neonate or adult mice show that neonatal recipients are more supportive of EG-driven leukemia when cell doses are adjusted for recipient size. Neonates exhibited a higher frequency of leukemia-initiating cells (LIC), enhanced expansion of EG/GFP + leukemic cells, and increased disease penetrance compared with adults at similar dose/size ratio, despite similar overall human hematopoietic engraftment. Leukemic cells arising in neonates and adults displayed comparable phenotypes and secondary transplantation capacities, indicating functional equivalence. Both CD34 + CD38 - and CD34 + CD38 + CB subpopulations were sensitive to EG-driven transformation, with neonates consistently showing higher LIC frequencies than adults. Together, our findings demonstrate that the developmental stage of the host microenvironment is a critical extrinsic determinant of EG-mediated leukemogenesis. Neonatal recipients constitute a physiologically relevant and highly sensitive model for studying pediatric AMKL initiation with low cell inputs, enabling refined investigation of microenvironmental signals that promote leukemia development and may reveal novel therapeutic vulnerabilities
Year:
2026
The transcription factor PAX5 is a major target of genetic alterations in human B-cell precursor acute lymphoblastic leukemia (B-ALL). Among the alterations, the P80R mutation affecting the DNA-binding domain represents the most frequent PAX5 point mutation in B-ALL. In contrast to other somatic PAX5 mutations, PAX5P80R defines a distinct B-ALL subtype characterized by a unique transcriptional program. In this study, we aimed to develop a model to elucidate the mechanism by which PAX5P80R perturbs normal B-cell differentiation and the oncogenic relays involved in PAX5P80R-driven malignant progression. A retroviral complementation approach of Pax5-deficient murine fetal liver cells demonstrated at the functional and molecular levels that PAX5P80R failed to rescue definitive B-cell commitment but maintained the repression of T-cell development. Moreover, PAX5P80R eventually led to clonal B-ALL transformation after transplantation through the acquisition of secondary mutations in genes involved in the JAK/STAT and RAS/MAPK pathways. Finally, transcriptomic analyses combined with pharmacologic investigation revealed ectopic activation of HIF2α as a common feature of B-ALL and identified acriflavine as a potent drug against B-ALL. Hence, this study provides a strategy to model the multistep process of B-ALL and sheds light on the biological mechanism by which the PAX5P80R mutation leads to leukemia. Significance: PAX5P80R perturbs normal B-cell development, leads to clonal transformation, and activates HIF2α as an oncogenic relay, providing mechanistic insights that could improve treatment of B-cell acute lymphoblastic leukemia.
Year:
2025
Supplementary figure 1. Sequencing-based analysis of CNA and LOH in adult LH-ALL. Supplementary figure 2. Representation of mutations in the frequent targeted genes in adult LH-ALL. Supplementary figure 3. Longitudinal assessment of TP53-mutant cell fraction as determined by ddPCR along with clonal IG/TR-based MRD quantification in three patients with undetectable TP53 mutation at remission. Supplementary figure 4. Merged single-cell analysis of cell-surface markers by ADT-sequencing of remission samples from three LH-ALL patients. Supplementary figure 5. Individual single-cell analyses of cell-surface markers by ADT-sequencing of remission samples from three LH-ALL patients. Supplementary figure 6. Individual analyses of single-cell immunophenotyping and genotyping of remission samples from three LH-ALL patients. Supplementary figure 7. Evaluation of allelic dropout rate on heterozygous single nucleotide polymorphism (SNPs) in remission samples. Supplementary figure 8. Individual single-cell analysis of cell-surface markers by ADT-sequencing of diagnosis samples from three LH-ALL patients. Supplementary figure 9. Single-cell genotyping of heterozygous SNPs allowing LOH assessment in diagnosis samples from three LH-ALL patients. Supplementary Figure 10. Distribution of single-cell genotypes of two LH-ALL patients with persistent TP53 and JAK2 (EI_046) or DNMT3A (EI_035) mutations in remission samples.
Year:
2025
Supplementary Table 1. Karyotypes of LH-ALL patients at diagnosis. Supplementary Table 2. Somatic variants detected in LH-ALL patients at diagnosis. Supplementary Table 3. ARCH related variants detected in LH-ALL patients at remission. Supplementary Table 4. Minimal residual disease values of remission samples used for mutation analysis. Supplementary Table 5. Somatic alterations in cell populations from diagnostic samples (BMMC) based on single-cell analyses. Supplementary Table 6. Somatic alterations in FACS-sorted cell populations from diagnostic samples. Supplementary Table 7. Panel of genes for targeted sequencing. Supplementary Table 8. Single cell DNA amplicons for genotyping and LOH analyses. Supplementary Table 9. Single cell DNA amplicons for B-ALL clono-specific IG/TR detection. Supplementary Table 10. ADT-seq panel and spike-in antibodies. Supplementary Table 11. Single cell sequencing metrics.
Year:
2025
Year:
2023
Year:
2023
Collaborators (13)
Beat W. Schäfer
University Children's Hospital
Nicolas Boissel
Université Paris Cité
Raphael Itzykson
MCU-PH
Université Paris Cité
Vahid Asnafi
-
Pedro Henrique de Lima Prata
MCU-PH
Université de Limoges
Patrice Chevallier
-
Christophe Antoniewski
Sorbonne Université
Ludovic Deriano
Principal Investigator
Institut Pasteur
Francoise Pflumio
INSERM
christine DIDIER
CNRS Delegation Occitanie Ouest
Bastien Gerby
Research Director at CNRS
Université de Toulouse
Aaron Mendez-Bermudez
INSERM
lionel adès
Professor
-
Make your next move.
Prepare your application
Review drafts before you send them.